myelomacrowd.org
FDA Lifts Hold on CANOVA Venetoclax Trial in Myeloma
The FDA has now lifted the partial hold on the Phase III CANOVA multiple myeloma trial using venetoclax with pomalidomide and dexamethasone. Venetoclax is a BCL-2 inhibitor that is being jointly developed between AbbVie and Roche. The hold was lifted after additional risk mitigation procedures and the implementation of new guidelines. Certain myeloma venetoclax studies went